Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater - ...
How can we tell if a depression treatment works beyond placebo? A new real-world method measuring placebo shows that ...
Andrew Nixon, spokesman for Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., announced on Thursday that moving forward, “all new vaccines will undergo safety testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results